AU657996B2 - Novel medical use for tachykinin antagonists - Google Patents

Novel medical use for tachykinin antagonists Download PDF

Info

Publication number
AU657996B2
AU657996B2 AU24583/92A AU2458392A AU657996B2 AU 657996 B2 AU657996 B2 AU 657996B2 AU 24583/92 A AU24583/92 A AU 24583/92A AU 2458392 A AU2458392 A AU 2458392A AU 657996 B2 AU657996 B2 AU 657996B2
Authority
AU
Australia
Prior art keywords
alkyl
phenyl
carbon atoms
optionally
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU24583/92A
Other languages
English (en)
Other versions
AU2458392A (en
Inventor
Keith Thomas Bunce
Russell Michael Hagan
Mark Ladlow
Alan Naylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU657996(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919120172A external-priority patent/GB9120172D0/en
Priority claimed from GB929202839A external-priority patent/GB9202839D0/en
Priority claimed from GB929204151A external-priority patent/GB9204151D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2458392A publication Critical patent/AU2458392A/en
Application granted granted Critical
Publication of AU657996B2 publication Critical patent/AU657996B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU24583/92A 1991-09-20 1992-09-18 Novel medical use for tachykinin antagonists Expired AU657996B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB919120172A GB9120172D0 (en) 1991-09-20 1991-09-20 Chemical compounds
GB9120172 1991-09-20
GB929202839A GB9202839D0 (en) 1992-02-11 1992-02-11 Chemical compounds
GB9202839 1992-02-11
GB9204151 1992-02-27
GB929204151A GB9204151D0 (en) 1992-02-27 1992-02-27 Medicaments

Publications (2)

Publication Number Publication Date
AU2458392A AU2458392A (en) 1993-03-25
AU657996B2 true AU657996B2 (en) 1995-03-30

Family

ID=27265859

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24583/92A Expired AU657996B2 (en) 1991-09-20 1992-09-18 Novel medical use for tachykinin antagonists

Country Status (14)

Country Link
US (7) US5360820A (enExample)
EP (4) EP0919245A3 (enExample)
JP (1) JP3020757B2 (enExample)
KR (1) KR100233323B1 (enExample)
AT (1) ATE195867T1 (enExample)
AU (1) AU657996B2 (enExample)
CA (1) CA2078578C (enExample)
DE (1) DE69231395T3 (enExample)
DK (1) DK0533280T4 (enExample)
ES (1) ES2149767T5 (enExample)
GR (1) GR3034682T3 (enExample)
IL (1) IL103214A (enExample)
PT (1) PT533280E (enExample)
TW (1) TW311139B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU666077B2 (en) * 1993-06-04 1996-01-25 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
DE69231395T3 (de) 1991-09-20 2005-07-21 Glaxo Group Ltd., Greenford Neue medizinische Indikation für Tachykinin-Antagonisten
US5444074A (en) * 1992-04-15 1995-08-22 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5637699A (en) * 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
GB9216911D0 (en) * 1992-08-10 1992-09-23 Merck Sharp & Dohme Therapeutic agents
US5837711A (en) * 1992-10-28 1998-11-17 Pfizer Inc. Substituted quinuclidines as substance P antagonists
US5886009A (en) * 1992-11-12 1999-03-23 Pfizer Inc. Quinuclidine derivative as a substance P antagonist
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
GB9305593D0 (en) * 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
GB9305718D0 (en) 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5496833A (en) * 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
DE69404306T2 (de) 1993-05-28 1997-10-30 Pfizer Verfahren zur herstellung und optischen auflösung von 2-phenyl-3-aminopiperidine
FR2710842B1 (fr) * 1993-10-07 1995-11-24 Rhone Poulenc Rorer Sa Nouvelle application thérapeutique de dérivés de perhydroisoindole.
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5491140A (en) * 1994-06-30 1996-02-13 Eli Lilly And Company Naphthyl tachykinin receptor antagonists to treat physiological conditions
CZ288434B6 (en) 1994-07-12 2001-06-13 Lilly Co Eli Dihydrochloride trihydrate of (R)-3-(1H-indol-3-yl)-1-[N-(2-methoxybenzyl)acetylamino]-2-[N-/2-(4-piperid-1-yl)piperid-1-yl)acetyl/-amino]propane, pharmaceutical preparation in which it is comprised and use thereof
WO1996014845A1 (en) * 1994-11-10 1996-05-23 Pfizer Inc. Nk-1 receptor antagonists for the treatment of eye disorders
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
RU2180852C2 (ru) * 1994-12-12 2002-03-27 Омерос Медикл Системс, Инк. Ингибирующий раствор и способ подавления боли, воспаления или спазма
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5565568A (en) * 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
AU5966196A (en) * 1995-06-08 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
WO1996041631A1 (en) * 1995-06-09 1996-12-27 Eli Lilly And Company Methods of treating cold and allergic rhinitis
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
FR2738742B1 (fr) * 1995-09-19 1997-11-14 Oreal Utilisation d'au moins une eau thermale de vichy en tant qu'antagoniste de substance p
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
GB9524104D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
NZ333062A (en) * 1996-06-26 2000-06-23 Warner Lambert Co Use of [R,S]-[2-(1H-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2yl methyl ester in the treatment of emesis
CA2260269A1 (en) * 1996-07-17 1998-01-22 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5773458A (en) * 1996-10-30 1998-06-30 American Home Products Corporation 1-azabicycloheptane derivatives
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
US6613765B1 (en) 1996-12-02 2003-09-02 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating major depressive disorders
JP2001504851A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 性的機能不全の治療のためのｎｋ−１受容体拮抗薬の使用
EP0942730A1 (en) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating bipolar disorders
CA2273809A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating movement disorders
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
DE69731657T2 (de) * 1996-12-02 2005-12-01 Merck Sharp & Dohme Ltd., Hoddesdon Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen
ATE293975T1 (de) * 1996-12-02 2005-05-15 Merck Sharp & Dohme Die verwendung von nk-1 rezeptor antagonisten für die behandlung von kognitiven störungen
US6114315A (en) * 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
US5846973A (en) * 1997-05-23 1998-12-08 Eli Lilly And Company Methods of treating pulmonary hypertension
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
CA2298777A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
EP1005454A4 (en) 1997-08-06 2003-01-15 Lilly Co Eli 2-ACYLAMINOPROPANAMINE FOR USE AS TACHYKININ RECEPTOR ANTAGONISTS
WO1999007681A1 (en) 1997-08-06 1999-02-18 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6087348A (en) * 1997-12-01 2000-07-11 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating stress disorders
US6271230B1 (en) 1997-12-01 2001-08-07 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating cognitive disorders
US6156749A (en) * 1997-12-01 2000-12-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
WO1999059583A1 (en) * 1998-05-18 1999-11-25 Merck & Co., Inc. Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia
GB9812662D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
AU1409100A (en) * 1998-11-27 2000-06-19 Takeda Chemical Industries Ltd. Drugs
NZ501211A (en) * 1999-01-29 2001-10-26 Pfizer Prod Inc Pharmaceutical composition comprising macrolide antibiotic like erythromycin and a Substance P antagonist, and method for treating cancer, bacterial and protozoal infection in non-humans
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
MXPA02004330A (es) 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
GB9927125D0 (en) 1999-11-16 2000-01-12 Univ Reading The Placental human neurokinin B precursor
TR200302077T4 (tr) * 1999-11-29 2004-01-21 F. Hoffmann-La Roche Ag 2-(3,5-Bis-Trifluorometil-fenil)-N-metil-N- (6-morfonil-4-il-4-O-tolil-piridin-3-il)- izobütiramit
BR0112350A (pt) 2000-07-11 2003-06-24 Albany Molecular Res Inc Composto, composição farmacêutica, e, método de tratar um animal afligido por um distúrbio neurológico ou psicológico
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
EP1205855A3 (en) * 2000-11-10 2006-01-25 Masae Yanagi Data managing method, data managing system, data managing apparatus, data handling apparatus, computer program, and recording medium
GB0108594D0 (en) * 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
US20030069296A1 (en) * 2001-08-24 2003-04-10 Wishka Donn G. Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
EP1297826A1 (en) * 2001-09-27 2003-04-02 Menarini Ricerche S.p.A. Nasal pharmaceutical compositions containing a NK-2 antagonist
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
WO2003066589A1 (en) * 2002-02-08 2003-08-14 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US20040001895A1 (en) * 2002-06-17 2004-01-01 Pfizer Inc. Combination treatment for depression and anxiety
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
RU2228752C1 (ru) * 2003-03-21 2004-05-20 Государственный научный центр - Институт биофизики Фармацевтическая композиция, содержащая ондансетрон и бензамид
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AR049419A1 (es) * 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
NZ549254A (en) * 2004-03-10 2010-06-25 Nycomed Gmbh Amido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
CA2573271C (en) 2004-07-15 2015-10-06 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2006089674A2 (en) 2005-02-25 2006-08-31 F.Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
KR101589551B1 (ko) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20090149462A1 (en) * 2006-08-28 2009-06-11 Hetero Drugs Limited Process for purification of aprepitant
PL2124556T3 (pl) 2006-10-09 2015-02-27 Charleston Laboratories Inc Kompozycje farmaceutyczne
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2674436C (en) 2007-01-10 2012-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
KR20090112722A (ko) 2007-01-24 2009-10-28 글락소 그룹 리미티드 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물
CL2008001162A1 (es) * 2007-04-24 2008-11-03 Takeda Pharmaceutical Compuestos derivados de piperidina, antagonista del receptor de taquiquinina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto para el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal, una enfermedad del sistema nervioso central.
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CA2749273C (en) 2008-01-09 2018-09-04 Charleston Laboratories, Inc. Pharmaceutical oral dosage form comprising a triptan and an antiemetic
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
EP2429296B1 (en) 2009-05-12 2017-12-27 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
SI2606134T1 (sl) 2010-08-17 2019-08-30 Sirna Therapeutics, Inc. RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US20140045832A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Insulin-Like Growth Factor-1 Receptor Inhibitors
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
HRP20201138T1 (hr) 2012-07-06 2020-10-30 Pharmathen S.A. Stabilan farmaceutski sastav za ubrizgavanje antagonista neurokinin 1 receptora i postupak pripreme istoga
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
JP6387013B2 (ja) 2012-12-20 2018-09-12 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｄｍ２阻害薬としての置換されたイミダゾピリジン類
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US10610532B2 (en) 2015-08-03 2020-04-07 Leiutis Pharmaceuticals Pvt. Ltd. Liquid formulations of fosaprepitant
US9913853B2 (en) 2015-11-03 2018-03-13 Cipla Limited Stabilized liquid fosaprepitant formulations
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
WO2019038656A1 (en) 2017-08-21 2019-02-28 Leiutis Pharmaceuticals Pvt, Ltd NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3091944A1 (en) 2018-02-26 2019-08-29 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
KR20210046009A (ko) 2018-08-07 2021-04-27 머크 샤프 앤드 돔 코포레이션 Prmt5 억제제
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048058A (en) * 1975-08-13 1977-09-13 Standard Oil Company (Indiana) Methods to be used in reforming processes employing multi-metallic catalysts
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
US4175129A (en) * 1975-07-21 1979-11-20 Janssen Pharmaceutica N.V. Antiemetic 1-(benzoxazolylalkyl)-piperidine derivatives
US4160836A (en) * 1976-05-17 1979-07-10 Janssen Pharmaceutica N.V. Antiemetic 1-(benzothiazolylalkyl)piperidine derivatives
GB2100259B (en) 1981-06-13 1984-10-31 Merrell Toraude & Co Treatment of migraine with tropyl benzoate derivatives
FR2557110B1 (fr) 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
GB8401888D0 (en) 1984-01-25 1984-02-29 Glaxo Group Ltd Heterocyclic compounds
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
EP0498466B1 (en) * 1985-04-27 2002-07-24 F. Hoffmann-La Roche Ag Indazole-3-carboxamide and -3-carboxylic acid derivatives
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US4910193A (en) * 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
ES2053451T3 (es) * 1986-01-07 1994-08-01 Beecham Group Plc Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US4839465A (en) * 1987-01-20 1989-06-13 Sterling Drug Inc. Di-(D-tryptophyl and/or tetrahydropyridoindolylcarbonyl)-containing peptide amides and process for preparation thereof
FR2610323B1 (fr) 1987-02-04 1989-06-23 Delalande Sa Enantiomeres de configuration absolue s de derives amide de l'amino-3 quinuclidine, leur procede de preparation et leur application en therapeutique
DE3711335A1 (de) 1987-04-03 1988-10-20 Merck Patent Gmbh Aminosaeurederivate
US5360800A (en) * 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
JPH01199575A (ja) 1988-02-04 1989-08-10 Rikagaku Kenkyusho 新規なサイクロマルトデキストリン・グルカノトランスフェラーゼ及びその製造法
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB8807246D0 (en) 1988-03-25 1988-04-27 Merck Sharp & Dohme Therapeutic agents
EP0363085A3 (en) * 1988-10-03 1991-03-27 Beecham Group Plc Novel compounds
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US4920227A (en) * 1988-11-29 1990-04-24 Rorer Pharmaceutical Corp. Benzobicyclic carboxamide 5-HT3 antagonists
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
CA2022886A1 (en) * 1989-08-08 1991-02-09 Raymond Baker Substituted pyridines, their preparation, formulations and use in dementia
IE77033B1 (en) 1989-08-16 1997-11-19 Univ Tulane Substance P antagonists
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
DE69020694T2 (de) * 1989-11-28 1996-01-18 Syntex Inc Tricyclische Verbindungen.
WO1991009844A1 (en) * 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5321032A (en) * 1990-02-15 1994-06-14 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds and pharmaceutical compositions thereof
DE4007869A1 (de) 1990-03-13 1991-09-19 Merck Patent Gmbh Aminosaeurederivate
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
HUT68667A (en) * 1990-09-28 1995-07-28 Pfizer Fused ring analogs of nitrogen containing nonaromatic heterocycles
GB9023116D0 (en) 1990-10-24 1990-12-05 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
DE4034829A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh Cyclopeptide
ATE154354T1 (de) * 1991-02-11 1997-06-15 Merck Sharp & Dohme Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung
EP0581777A1 (en) 1991-03-26 1994-02-09 Pfizer Inc. Stereoselective preparation of substituted piperidines
EP0589924B1 (en) 1991-06-20 1996-09-04 Pfizer Inc. Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
TW202432B (enExample) 1991-06-21 1993-03-21 Pfizer
US5629347A (en) 1991-07-05 1997-05-13 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
DE69231395T3 (de) * 1991-09-20 2005-07-21 Glaxo Group Ltd., Greenford Neue medizinische Indikation für Tachykinin-Antagonisten
US6048859A (en) * 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5393762A (en) 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
JP3503768B2 (ja) * 1995-01-06 2004-03-08 関西電力株式会社 溝掘削機の制御装置
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
ZA985765B (en) * 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU666077B2 (en) * 1993-06-04 1996-01-25 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Also Published As

Publication number Publication date
US5538982A (en) 1996-07-23
DE69231395T2 (de) 2001-02-01
US7214692B2 (en) 2007-05-08
KR930017563A (ko) 1993-09-20
DE69231395T3 (de) 2005-07-21
IL103214A (en) 1999-03-12
IL103214A0 (en) 1993-02-21
DK0533280T3 (da) 2001-01-02
DE69231395D1 (de) 2000-10-05
JP3020757B2 (ja) 2000-03-15
EP0916346A3 (en) 2000-12-06
ATE195867T1 (de) 2000-09-15
ES2149767T5 (es) 2005-06-16
GR3034682T3 (en) 2001-01-31
EP0533280A1 (en) 1993-03-24
EP0916346A2 (en) 1999-05-19
US5360820A (en) 1994-11-01
ES2149767T3 (es) 2000-11-16
EP0533280B2 (en) 2004-12-01
KR100233323B1 (ko) 1999-12-01
US7342028B2 (en) 2008-03-11
EP1082959A1 (en) 2001-03-14
US5798363A (en) 1998-08-25
CA2078578C (en) 2002-02-05
EP0919245A3 (en) 2000-11-15
EP0919245A2 (en) 1999-06-02
US20020052351A1 (en) 2002-05-02
AU2458392A (en) 1993-03-25
DK0533280T4 (da) 2005-02-28
US6191139B1 (en) 2001-02-20
EP0533280B1 (en) 2000-08-30
TW311139B (enExample) 1997-07-21
PT533280E (pt) 2001-01-31
JPH06107563A (ja) 1994-04-19
US20050085414A1 (en) 2005-04-21
CA2078578A1 (en) 1993-03-21
US6326383B1 (en) 2001-12-04

Similar Documents

Publication Publication Date Title
AU657996B2 (en) Novel medical use for tachykinin antagonists
USRE46417E1 (en) Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
JP4295985B2 (ja) 新規なキヌクリジン誘導体およびそれを含む医薬組成物
US6812236B2 (en) Compounds useful in therapy
US12006314B2 (en) Anti-cancer nuclear hormone receptor-targeting compounds
JPH06500124A (ja) セロトニン作動性５―ｈｔ３拮抗薬として新規イミダゾピリジン
SK43696A3 (en) (r)-5-carbamoyl-8-fluoro-3-n, n-disubstituted amino-3,4-dihydro- -2h-1-benzopyranes
JPH10316567A (ja) 過敏性腸症候群の症状の治療用のｎｋ−１受容体アンタゴニスト
RU2382041C2 (ru) Новые сложные эфиры кватернизованного хинуклидина
HK1018593A (en) Nk-1 receptor antagonist and a systemic antiinflammatory corticosteroid for the treatment of emesis
HK1018594A (en) Nk-1 receptor antagonists and 5ht3 receptor antagonists for the treatment of emesis
US20010007872A1 (en) Method of treating acute, chronic and/or neuropathic pain
JPH0378862B2 (enExample)
TWI293299B (en) Novel quinuclidine derivatives and medicinal compositions containing the same